Our Team
Our world-class team of scientists, doctors, biotechnology innovators, global sales leaders of tier-one medical device companies, and venture capitalists have a proven track record of delivering state of the art advanced treatment and diagnostic solutions for more than 30 years and guiding many successful startups to IPOs and acquisitions by Fortune 100 companies. With advanced degrees from Princeton and Dartmouth, affiliations with MIT and major surgical centers, and extensive experience developing highly regarded biotechnology products and valuable intellectual property, we focus on delivering biotechnology solutions that address critical care needs.
Developments
Status as of March 2024
- Finalizing the third round of funding.
- Finalizing the recruitment of a highly regarded industry veteran as the new CEO.
- Partnering with distributors who will grow a strong base of practitioners who use our device because it has been demonstrated to significantly improve outcomes.
- Identified a high-value market segment with a very high potential for establishing our product as the standard of care for the critical procedures these doctors perform.
- Updating marketing and financial models based on new proprietary research
- 2022, established international patent protections in significant markets worldwide.
- King & Spalding filed the PCT application in April 2021
- October 2020, began early field trials. Surgeons are using kits in their practice.
- July 2020: Began contract manufacturing.
- May 2019, series A funding 105% subscribed; 2020, 2nd round raise completed.
News
- Welcomed medical device industry veterans Gopalkrishnan Mohan and John Gormally. Mohan brings business development experience at Becton Dickinson and C-level leadership experience at ERBA. John brings the storied experience of a 37-year career in medical device and clinical diagnostics General Management, Sales and Marketing, including VP of Global Sales at BD.
- Duke University produced a decision-analytic cost-consequence model that provides a flexible approach to estimate the current economic impact in the US of complications resulting from the use of the existing product that the SCV device replaces.
- Timothy C. Crowley, Chief Operating Officer: Tim has over 40 years of experience in the Medical Device Industry. He began his career with the first minimally invasive surgical company, Acufex. Tim served Acufex as Director of International Sales until the sale of the company to Smith and Nephew. He went on to manage global operations for several medical device companies through growth and exit stages. Tim began investing in and consulting for medical start-ups in the early 2000s. Serving as the Senior Distribution Consultant for the Emergo Group for over 10 years, Tim developed go-to-market strategies for over 200 clients. For a select few of these, he acted as interim CEO or COO. Tim has a BA from the University of Pennsylvania, an MBA from Columbia University, and is fluent in French, German, Italian, and Spanish.
- Dave Smith, Sr. Vice President of Engineering and Compliance: Dave is a medical device industry expert who was formerly General Manager at Galt Medical, VP of Research and Development for Horizon Medical Products, Director of Marketing and R&D for RITA Medical Systems, Director of R&D for Angiodynamics, and President and Chief Technology Officer at TransCardiac Therapeutics. A serial inventor with two issued patents (6,676,633, Needle safety device & 6,997,914, Novel Vascular Access Device), 6 Patents pending for Angiodynamics, 5 for TransCardiac Therapeutics, and 5 personally held. He has a BSME from Florida State University and an MBA from the University of West Virginia. Dave enjoys scuba diving and teaching the next generation of robotics engineers.
- King & Spalding filed a provisional patent in April 2020
- Welcomed Don Hutchison as a member and adviser. Don has guided hundreds of successful startups, 6 to IPOs, and many to acquisition by Fortune 100 companies.
- Formed SCV Delivery Systems LLC in April 2019 and funded in May 2019.